Skip to main content

GDRX

Stock
Health Care
Health Information Services

Performance overview

GDRX Price
Price Chart

Forward-looking statistics

Beta
1.00
Risk
57.10%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.

Company info

SectorHealth Care
IndustryHealth Information Services
Employees793
Market cap$3.2B

Fundamentals

Enterprise value$2.0B
Revenue$797.4M
Revenue per employee
Profit margin3.57%
Debt to equity82.71

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$0.07
Dividend per share
Revenue per share$2.08
Avg trading volume (30 day)$7M
Avg trading volume (10 day)$9M
Put-call ratio

Macro factor sensitivity

Growth+0.1
Credit+4.2
Liquidity-3.6
Inflation-5.3
Commodities-0.7
Interest Rates-1.6

Valuation

Dividend yield0.00%
PEG Ratio11.49
Price to sales2.11
P/E Ratio11.49
Enterprise Value to Revenue2.53
Price to book2.60

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

GDRX vs. HQY: Which Stock Is the Better Value Option?

Investors with an interest in Medical Services stocks have likely encountered both GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

Zacks Investment Research (July 9, 2025)
GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst

JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings GDRX following the company's first-quarter earnings.

Benzinga (May 19, 2025)
Digital health companies got pummeled by Wall Street in 2024 as industry adapts to post-Covid slowdown

It's been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling from the aftermath. According to a CNBC analysis of 39 public digital health companies, around two-thirds have lost value this year, while the Nasdaq is up 32%.

CNBC (December 24, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free